fexofenadine has been researched along with Long QT Syndrome in 9 studies
fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arsenic trioxide (As2O3) has been verified as a breakthrough in the management of acute promyelocytic leukemia in recent decades." | 3.85 | Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism. ( Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M, 2017) |
| "The long QT syndrome is a rare disease." | 1.33 | Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs. ( Codreanu, A; de Chillou, C; Moneret-Vautrin, DA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Recanatini, M | 1 |
| Yan, M | 1 |
| Feng, L | 1 |
| Shi, Y | 1 |
| Wang, J | 1 |
| Liu, Y | 1 |
| Li, F | 1 |
| Li, B | 1 |
| Couderc, JP | 1 |
| Lehman, JM | 1 |
| Blaiss, MS | 1 |
| Moneret-Vautrin, DA | 1 |
| de Chillou, C | 1 |
| Codreanu, A | 1 |
| Pinto, YM | 1 |
| van Gelder, IC | 1 |
| Heeringa, M | 1 |
| Crijns, HJ | 1 |
| Shuster, J | 1 |
| Dhar, S | 1 |
| Hazra, PK | 1 |
| Malakar, S | 1 |
| Mistri, G | 1 |
| Rajamani, S | 1 |
| Anderson, CL | 1 |
| Anson, BD | 1 |
| January, CT | 1 |
1 review available for fexofenadine and Long QT Syndrome
| Article | Year |
|---|---|
Selecting the optimal oral antihistamine for patients with allergic rhinitis.
Topics: Administration, Oral; Cardiovascular System; Central Nervous System; Cetirizine; Drug Interactions; | 2006 |
8 other studies available for fexofenadine and Long QT Syndrome
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go- | 2002 |
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK2 | 2017 |
QT interval prolongation and beyond.
Topics: Animals; Anti-Allergic Agents; Dogs; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Terf | 2006 |
Long QT syndrome in a patient with allergic rhinoconjunctivitis and auto-immune diabetes: focus on the choice of anti-H1 drugs.
Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Asthmatic Agents; Butyrophenones; Cetirizine; Conjunct | 2006 |
QT lengthening and life-threatening arrhythmias associated with fexofenadine.
Topics: Aged; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male; Syncope; Tachyc | 1999 |
Fexofenadine and prolonged QT intervals.
Topics: Aged; Drug Monitoring; Electrocardiography; Histamine H1 Antagonists; Humans; Long QT Syndrome; Male | 1999 |
Fexofenadine-induced QT prolongation: a myth or fact?
Topics: Controlled Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Long QT Syndrome; Terfenadine | 2000 |
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Topics: Anti-Arrhythmia Agents; Cell Line; Dose-Response Relationship, Drug; Electric Conductivity; ERG1 Pot | 2002 |